This article is more than 5 years old. Information may no longer be current.
Prostaglandin analogues may reduce central corneal thickness
Topical therapy using prostaglandin analogues may decrease central corneal thickness, a study found.
The analysis randomized 50 patients with primary open-angle glaucoma, six patients with normal tension glaucoma and 13 patients with ocular hypertension to monotherapy with either Xalatan (latanoprost 0.005%, Pfizer), Travatan Z (travoprost 0.004%, Alcon) or Lumigan (bimatoprost 0.03%, Allergan). Mean follow-up was 17.19 ± 15.71 months.
A statistically significant lowering of central corneal thickness occurred for all groups (P < .001), with no significant difference among the three groups. Furthermore, no significant difference in outcomes occurred for patients with 6 months or less of therapy and patients with longer therapy, suggesting that thinning primarily occurs during the early months of treatment.
The authors noted that the study did not assess how central corneal thickness reductions correlated with IOP levels and suggested future research using larger samples to analyze the influence on IOP.